Contact this trialFirst, we need to learn more about you.
Alkylating Agent
CPI-613 + Chemotherapy for Biliary Tract Cancer
Recruiting1 awardPhase 1 & 2
Tucson, Arizona
This trial is testing a new drug, CPI-613, to see if it's safe and effective in treating biliary tract cancer when used with standard chemotherapy. There are two parts to the trial, and in the second part patients are randomly assigned to either receive CPI-613 or not. Researchers will compare how well patients do in each group.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service